DKK1 and AL amyloidosis: Compared with others vaccine groups, the results showed that hDKK1-hHSP70 DNA fusion vaccine could markedly inhibit tumor growth and prolong the survival against murine multiple myeloma models through inducing humoral and cellular tumor-specific immune responses.